• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Inhibrx Biosciences (INBX) Shares Moved, What Is Driving Attention Now?

    Simply Wall St·09/29/2026 15:13:41
    語音播報

    Inhibrx Biosciences (INBX) has drawn fresh attention after recent trading left the stock at a last close of US$101.71. Recent price swings now sit alongside a sharp 1 year total return figure.

    For Inhibrx Biosciences, the recent share price pullback, with a 7 day share price return down 9.22% and a 30 day share price return down 17.58%, sits against a stronger backdrop that includes a 90 day share price return of 7.35%, a year to date share price return of 35.54%, and a very large 1 year total shareholder return of 214.79%. Together, these figures point to strong longer term momentum despite near term softness.

    Scan beyond Inhibrx Biosciences and review other high momentum biotech and healthcare names through our curated list of 37 healthcare AI stocks in one place.

    The surge in Inhibrx Biosciences over the past year, followed by this recent pullback, forces a simple choice. Do you lean into the volatility now, or wait for a cleaner entry as the valuation picture comes into focus?

    Preferred Multiple of Price-to-Book: Is it justified?

    Valuation work on Inhibrx Biosciences hits an immediate snag. The stock carries a P/B ratio of roughly -28.3x, which comes from its negative shareholder equity position rather than any premium investors are willingly paying.

    A negative P/B figure means the traditional multiple does not give a clean anchor for what the market might be willing to pay for each dollar of net assets. The issue is not a single quarter; liabilities exceed assets, so the usual book value framework does not line up neatly with the current market capitalization of about $1.47b.

    In situations like this, investors often fall back on a discounted cash flow approach instead. The SWS DCF model projects future cash flows for a business, then discounts those streams back to today using a required rate of return, which gives a single estimate of what those future dollars might be worth in present terms.

    For a clinical-stage biotech such as Inhibrx Biosciences, that kind of framework can be more relevant than book value. Revenue is currently below $1m and the company reported a loss of $138.181m, while forecasts point to rapid top line expansion alongside ongoing losses over the next three years. Cash generation and funding needs tend to matter more than accounting equity in that kind of profile, which is why a DCF lens often becomes the primary tool.

    Look into how the SWS DCF model arrives at its fair value.

    Result: DCF Fair value of $XX (ABOUT RIGHT)

    Still, the story around Inhibrx Biosciences can change quickly if clinical data disappoints or if funding needs intensify before any clear revenue ramp appears.

    Find out about the key risks to this Inhibrx Biosciences narrative.

    Next Steps

    Mixed signals around Inhibrx Biosciences can feel confusing, so consider reviewing the full risk and reward picture promptly and then shape your own call with 2 key rewards and 3 important warning signs

    Looking for more investment ideas beyond Inhibrx Biosciences?

    If Inhibrx Biosciences has you thinking harder about risk, return, and timing, broaden your watchlist now so you are not relying on a single story.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.